HRTX vs. MRVI, ELVN, PAHC, ZYME, ABCL, REPL, COLL, RCKT, EOLS, and PHVS
Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Maravai LifeSciences (MRVI), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Zymeworks (ZYME), AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
Heron Therapeutics vs.
Maravai LifeSciences (NASDAQ:MRVI) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.
50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 0.6% of Maravai LifeSciences shares are held by insiders. Comparatively, 5.8% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Maravai LifeSciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
Heron Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. Heron Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Heron Therapeutics received 603 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 68.84% of users gave Heron Therapeutics an outperform vote while only 62.63% of users gave Maravai LifeSciences an outperform vote.
Maravai LifeSciences currently has a consensus price target of $10.28, suggesting a potential upside of 150.15%. Heron Therapeutics has a consensus price target of $5.67, suggesting a potential upside of 227.55%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Maravai LifeSciences.
Heron Therapeutics has a net margin of -20.31% compared to Maravai LifeSciences' net margin of -81.13%. Heron Therapeutics' return on equity of 0.00% beat Maravai LifeSciences' return on equity.
In the previous week, Maravai LifeSciences had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for Maravai LifeSciences and 3 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.53 beat Maravai LifeSciences' score of 0.27 indicating that Heron Therapeutics is being referred to more favorably in the news media.
Summary
Heron Therapeutics beats Maravai LifeSciences on 12 of the 18 factors compared between the two stocks.
Get Heron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Heron Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HRTX) was last updated on 2/22/2025 by MarketBeat.com Staff
